Related Experiment Video
Updated: Jun 2, 2026
Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
Published on: April 3, 2026
Optimal duration of imatinib mesylate therapy in metastatic gastrointestinal stromal tumours
1W.P. Holman Clinic Launceston General Hospital, Launceston, Tas., Australia.
Abstract:
While current literature provides evidence that imatinib mesylate has significant activity in patients with advanced and metastatic gastrointestinal stromal tumour (GIST), and highlights the potential for the development of anticancer drugs based on specific molecular abnormalities present in cancers, specific recommendations concerning the optimal duration of therapy remain controversial. This case presents the favourable outcome of a patient who originally presented almost 9 years ago with widespread, bulky, metastatic GIST involving the abdomen and pelvis. A sustained, complete response was achieved with imatinib and prompted an interruption in treatment 7 years after initial presentation. The disease reoccurred extensively within 9 months of treatment interruption, but once again rapidly completely responded to the recommencement of imatinib, with that response being now maintained for over 9 months. This report suggests that dramatic and durable responses to imatinib can be achieved in individual cases despite the lack of specific guidelines in the literature with respect to defining how long treatment with imatinib should be continued in the absence of evidence of tumour progression.
Insights
This case study shows that extended imatinib mesylate therapy can lead to durable responses in metastatic gastrointestinal stromal tumour (GIST) patients. Stopping and restarting imatinib successfully managed recurrent GIST, suggesting individualized treatment durations may be beneficial.
Area of Science:
- Oncology
- Pharmacology
- Gastroenterology
Background:
- Gastrointestinal stromal tumour (GIST) is a rare sarcoma with metastatic potential.
- Imatinib mesylate is a targeted therapy demonstrating significant activity in advanced GIST.
- Optimal duration of imatinib therapy for GIST remains a subject of clinical debate.
Observation:
- A patient with widespread, bulky, metastatic GIST achieved a complete response to imatinib.
- Treatment was interrupted after 7 years, leading to extensive disease recurrence within 9 months.
- Recommencing imatinib resulted in a rapid and complete response, maintained for over 9 months.
Findings:
- This case demonstrates that imatinib can induce dramatic and durable responses in GIST.
- Successful management of recurrent GIST was achieved by reinitiating imatinib therapy.
- Individualized treatment duration for imatinib may be effective in select GIST cases.
Implications:
- This case suggests that prolonged or intermittent imatinib therapy can be a viable strategy for managing metastatic GIST.
- Further research into personalized treatment durations for imatinib in GIST is warranted.
- Clinicians may consider individualized imatinib treatment based on patient response and recurrence patterns.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...